MedTrace Logo

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

NCT00300430 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1911

Last updated 2009-07-23

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.

Conditions

Interventions

DRUG

ABT-335 and rosuvastatin calcium

ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks

DRUG

ABT-335 and atorvastatin calcium

ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks

DRUG

ABT-335 and simvastatin

ABT-335 135 mg plus simvastatin daily, 52 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300430 on ClinicalTrials.gov